Alnylam Pharmaceuticals | ALNY - Trade Creditors


Alnylam Pharmaceuticals reported $115.72M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
Arrowhead Research USD 32.94M 15.26M Dec/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Incyte USD 1.63B 1.46B Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Moderna USD 317M 50M Dec/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novartis USD 4.56B 49M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
Takeda JPY 467.59B 28.61B Dec/2025
Tectonic Therapeutic USD 1.48M 1.32M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025
Xencor USD 10.83M 1.75M Dec/2025